GenoSafe is a service company specialised in the evaluation of the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …).


GenoSafe was incorporated in 2003 and became operational in 2004. Its two shareholders are Genethon and the French Muscular Dystrophy Association (AFM).

Description of the products/services/technology

GenoSafe advises and assists its clients in fulfilling their testing needs, from research through to clinical trials:

  • specific assays and analytical methods: development and validation
  • samples analysis: custom studies

Our broad range of services is based on expertise in a number of complementary fields:

  • molecular analyses (including Biodistribution studies for gene transfer products)
  • evaluation of immune responses
  • quality control of gene therapy products for preclinical and clinical use

We provide professional advice, guidance and management for ensuring optimal progress of projects

Customer references/collaborations/highlights

  • GenoSafe’s European clientele is composed of biotech firms, pharmaceutical companies and academic labs.
  • GenoSafe is a partner in various French and European collaborative projects.
  • GLP compliance certificate



Muriel Audit Muriel Audit

Holder of a PhD in Biology from the Montpellier II University, Muriel takes the position of Analytical Methods Development Manager at Genethon in 1999. She mainly focuses her work on control methods of gene therapy trials with viral vectors, specifically biosafety tests used in the frame of the first European gene therapy trial with an HIV derived vector.

More Info


Séverine Pouillot Séverine Pouillot

After completing her PhD work on the validation of transfer methods of human embryonic stem cells for the cardiomyopathy associated to Duchenne muscular Dystrophy therapy, Séverine Pouillot joined Genosafe in March 2008. She is in charge of follow-up of national and European collaborative projects in which Genosafe is involved.

More Info


Vincent Zuliani Vincent Zuliani

Prior to his appointment at GenoSafe's Business Development Manager in March 2005, Vincent Zuliani was responsible for the management of gene therapy production projects at Genethon. After finishing his scientific training at UCSF (University of California, San Francisco), he held various research positions in the life science industry.

More Info